Portal de Periódicos da CAPES

Circulating microRNAs: novel biomarkers for early detection of colorectal cancer

2015; Elsevier BV; Volume: 166; Issue: 3 Linguagem: Inglês

10.1016/j.trsl.2015.04.007

1931-5244

Rajagopal N. Aravalli, Clifford J. Steer,

Circular RNAs in diseases

Article on page 225. Differential expression of circulating microRNAs according to severity of colorectal neoplasia Ho GYF, Jung HJ, Schoen RE, Wang T, Lin J, Williams Z, Weissfeld JL, Park JY, Loudig O, and Suh Y Colorectal cancer (CRC) is the third most common cancer in the United States, 1 American Cancer SocietyCancer facts & figures. American Cancer Society, Atlanta2012 Google Scholar and about 1.2 million individuals are diagnosed each year with CRC worldwide. 2 Ferlay J. Shin H.R. Bray F. Forman D. Mathers C. Parkin D.M. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010; 127: 2893-2917 Crossref PubMed Scopus (13611) Google Scholar Although tumor resection is the most common curative treatment option for about two-thirds of patients with CRC, recurrence rates are very high (28%–50%) and pose a serious challenge to reducing mortality in these individuals. 3 Carpentier M.Y. Vernon S.W. Batholomew L.K. Murphy C.C. Bluethmann S.M. Receipt of recommended surveillance among colorectal cancer survivors: a systematic review. J Cancer Surviv. 2013; 7: 464-483 Crossref PubMed Scopus (44) Google Scholar Five-year survival of patients with localized CRC is 90% after surgery. 4 Pfister D.G. Benson 3rd, A.B. Somerfield M.R. Clinical practice. Surveillance strategies after curative treatment of colorectal cancer. N Engl J Med. 2004; 350: 2375-2382 Crossref PubMed Scopus (133) Google Scholar About 50% of patients with CRC develop metastasis, after which the 5-year survival rate drops to 60% in these individuals contributing to the increased rate of mortality. 5 Van Cutsem E. Cervantes A. Nordlinger B. Arnold D. ESMO Guidelines Working GroupMetastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014; 25: iii1-iii9 Crossref PubMed Scopus (820) Google Scholar In the absence of a specific risk factor for this disease, prognosis is typically based on the extent of tumor at diagnosis. The detection of early stage disease and improved surveillance has reduced mortality rates, as shown recently in a 30-year follow-up study. 6 Shaukat A. Mongin S.J. Geisser M.S. et al. Long-term mortality after screening for colorectal cancer. N Engl J Med. 2013; 369: 1106-1114 Crossref PubMed Scopus (592) Google Scholar Therefore, early detection is critical to effectively treating CRC, and novel biomarkers are urgently needed for this purpose. Article on page 225. Differential expression of circulating microRNAs according to severity of colorectal neoplasia Ho GYF, Jung HJ, Schoen RE, Wang T, Lin J, Williams Z, Weissfeld JL, Park JY, Loudig O, and Suh Y Differential expression of circulating microRNAs according to severity of colorectal neoplasiaTranslational ResearchVol. 166Issue 3PreviewThere is a need to develop a colorectal cancer (CRC) screening test that is noninvasive, cost effective, and sensitive enough to detect preneoplastic lesions. This case-control study examined the feasibility of using circulating extracellular microRNAs (miRNAs) to differentiate a spectrum of colorectal neoplasia of various severity and hence for early detection of colorectal neoplasia. Archived serum samples of 10 normal controls and 31 cases, including 10 with nonadvanced adenoma, 10 with advanced adenoma, and 11 with CRC, were profiled for circulating miRNAs using next-generation sequencing. Full-Text PDF